Publicaciones en las que colabora con BELLINDA BENHAMÚ SALAMA (56)

2023

  1. Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota-Inspired Synthetic Compound Targeting NPM1 for Leukemia

    JACS Au

2022

  1. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1Receptor for Parkinson's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 18, pp. 12256-12272

  2. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "diabesity"

    Journal of Medicinal Chemistry, Vol. 65, Núm. 7, pp. 5449-5461

  3. New Trends in Aging Drug Discovery

    Biomedicines, Vol. 10, Núm. 8

2019

  1. Allosteric modulators targeting GPCRs

    GPCRs: Structure, Function, and Drug Discovery (Elsevier), pp. 195-241

2017

  1. A Positive Allosteric Modulator of the Serotonin 5-HT2C Receptor for Obesity

    Journal of Medicinal Chemistry, Vol. 60, Núm. 23, pp. 9575-9584

  2. A new serotonin 5-HT 6 receptor antagonist with procognitive activity - Importance of a halogen bond interaction to stabilize the binding

    Scientific Reports, Vol. 7

  3. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells

    Oncotarget, Vol. 8, Núm. 7, pp. 11600-11613

2016

  1. Chemoproteomic approach to explore the target profile of GPCR ligands: Application to 5-HT1A and 5-HT6 receptors

    Chemistry - A European Journal, Vol. 22, Núm. 4, pp. 1313-1321

2015

  1. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

    International Journal of Cancer, Vol. 136, Núm. 9, pp. 2078-2090

2014

  1. Serotonin 5-HT6receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease

    Journal of Medicinal Chemistry, Vol. 57, Núm. 17, pp. 7160-7181

  2. The extracellular entrance provides selectivity to serotonin 5-HT 7 receptor antagonists with antidepressant-like behavior in vivo

    Journal of Medicinal Chemistry, Vol. 57, Núm. 15, pp. 6879-6884

2013

  1. New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo

    Journal of Medicinal Chemistry, Vol. 56, Núm. 20, pp. 7851-7861

2012

  1. New synthetic inhibitors of fatty acid synthase with anticancer activity

    Journal of Medicinal Chemistry, Vol. 55, Núm. 11, pp. 5013-5023

2011

  1. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines

    Breast Cancer Research, Vol. 13, Núm. 6

  2. Development of non-peptide ligands of growth factor receptor-bound protein 2-src homology 2 domain using molecular modeling and NMR spectroscopy

    Journal of Medicinal Chemistry, Vol. 54, Núm. 4, pp. 1096-1100

  3. New serotonin 5-HT 1A receptor agonists with neuroprotective effect against ischemic cell damage

    Journal of Medicinal Chemistry, Vol. 54, Núm. 23, pp. 7986-7999

  4. The importance of solvation in the design of ligands targeting membrane proteins

    MedChemComm, Vol. 2, Núm. 3, pp. 160-164

2010

  1. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation

    Journal of Medicinal Chemistry, Vol. 53, Núm. 3, pp. 1357-1369

  2. Development of fluorescent ligands for the human 5-HT1A receptor

    ACS Medicinal Chemistry Letters, Vol. 1, Núm. 6, pp. 249-253